Pharmafile Logo

MK-3102

- PMLiVE

Victoza cuts cardiovascular risk in landmark study

Novo Nordisk’s diabetes therapy outcomes ‘beyond expectations’

- PMLiVE

Novo creates online diabetes management resource

Aims to educate UK patients and the public on the signs and impact of hypos

Sanofi reception

Sanofi boosted by iGlarLixi trials at ADA

Combination of Lantus and Lyxumia showed greater efficacy in controlling type 2 diabetes

- PMLiVE

Merck buys cough drug developer Afferent for $1.25bn

Gains access to pipeline with potential for development in ‘neurogenic’ indications

Roche Basel Switzerland

Roche’s Tecentriq works as first-line bladder cancer therapy

New trial data presented at ASCO supports wider use of the drug

- PMLiVE

Roche picks up European rights to diabetes implant

Will distribute Senseonics' Eversense CGM System in Germany, Italy and the Netherlands

Gilead Sciences

Gilead, Merck get CHMP backing for new hep C combinations

Approval of Epclusa and Zepatier will see the pan-genotypic drugs compete for market share

- PMLiVE

Medtronic and Qualcomm to work on new diabetes sensors

Will initially collaborate on a single-use wireless continuous glucose monitoring system

Sanofi reception

FDA panel backs Sanofi’s insulin/GLP-1 agonist combo

iGlarLixi secures endorsement despite concern over its dosing and delivery device

Eli Lilly HQ

Lilly planning 20 new launches by 2023

Will focus on diabetes, immunology, oncology, neurodegeneration and pain

- PMLiVE

FDA advisors back Novo Nordisk’s IDeglira combination

Unanimous vote is a step forward for the Tesiba-Victoza injection

National Institute for Health and Care Excellence NICE logo

NICE backs freer use of SGLT2 inhibitors for diabetes

Recommendation positions Invokana, Forxiga and Jardiance as first-line treatments

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links